Word

OXFORD BIOMEDICA SOLUTIONS

Status

Pending

Status Code

688

Status Date

Tuesday, December 26, 2023

Serial Number

97361222

Mark Type

4000

Filing Date

Wednesday, April 13, 2022

Published for Opposition

Tuesday, October 31, 2023

Trademark Owner History

Oxford BioMedica Plc - Owner At Publication

Classifications

40 Custom manufacture of products relating to biotechnology; manufacture of gene therapy, and viral, retroviral, lentiviral and non-viral preparations and biopharmaceutical products; manufacture of biotechnology products; manufacture of viral and non-viral vectors; manufacture of vaccines

5 Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases, vaccines; pharmaceutical substances and preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by bacteria, viruses and parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; gene therapy products, namely, nanoparticles, viral vectors, retroviral vectors, lentiviral vectors and non-viral vectors for the delivery of genes to cells, all for medical purposes; vaccine manufacturing preparations; viral vaccines, namely, viral vector, retroviral vector, lentiviral vector and non-viral vector preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by bacteria, viruses and parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; biochemical and chemical products for use in medical science, namely, viral vectors; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes

45 Preparation and review of reports for regulatory approval of pharmaceuticals and bioceuticals; licensing of intellectual property; regulatory compliance consulting in the field of chemistry manufacturing and controls (CMC) activities

44 Medical diagnostic testing; information relating to pharmaceuticals, bioceuticals and advanced therapy medicinal products; providing medical information to medical professionals in the form of reports in the field of biotechnology, gene therapy and cell therapy; consultancy, advice and information in the field of clinical trials, healthcare, pharmaceuticals and advanced therapy medicinal products; medical advisory services relating to vaccination regimes; medical advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases, reproductive system disorders, and pharmaceutical and biochemical preparations for contraceptive purposes, in humans and animals

42 Scientific research and development services in the field of biochemistry and genetic engineering; biochemistry engineering; genetic engineering; design of manufacturing facilities; quality control for others; scientific and technological services, namely, testing and validation services in the fields of gene and cell therapy and biotechnology; product development consultancy in the field of nanotechnology, gene therapy and vector-based delivery systems; medical and scientific laboratory services; scientific and technological services, namely, scientific research, development and analysis in the fields of gene and cell therapy and biotechnology; industrial analysis services, namely, analysis of viral vectors and gene therapy products to assure compliance with medical and pharmaceutical industry standards; provision of scientific information in the field of biotechnology, gene therapy and cell therapy; research and scientific analysis relating to drug discovery and development for others; scientific research in the nature of conducting clinical trials for others; manufacture of viral vectors, gene therapy and cell therapy products; product and manufacturing process development in the fields of biotechnology, gene therapy and cell therapy

"OXFORD" AND "SOLUTIONS"

Trademark Events

Dec 26, 2023

Noa E-Mailed - Sou Required From Applicant

Oct 31, 2023

Official Gazette Publication Confirmation E-Mailed

Oct 31, 2023

Published For Opposition

Oct 11, 2023

Notification Of Notice Of Publication E-Mailed

Sep 20, 2023

Approved For Pub - Principal Register

Sep 14, 2023

Teas/Email Correspondence Entered

Sep 14, 2023

Correspondence Received In Law Office

Sep 14, 2023

Assigned To Lie

Apr 28, 2023

Teas Response To Office Action Received

Feb 3, 2023

Notification Of Non-Final Action E-Mailed

Feb 3, 2023

Non-Final Action E-Mailed

Feb 3, 2023

Non-Final Action Written

Jan 31, 2023

Assigned To Examiner

Apr 19, 2022

New Application Office Supplied Data Entered

Apr 16, 2022

New Application Entered